Business · 06/12/2010Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for STELARA Patent Extension
Summary
The Food and Drug Administration has officially confirmed the review period for Pfizer's STELARA patent extension, following a submission to the US Department of Commerce for patent extension of the human biological product.
Original source language: Federal Register — Health and Human ServicesOpen original release →